Compare EFSI & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EFSI | LRMR |
|---|---|---|
| Founded | 1881 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.1M | 253.5M |
| IPO Year | 1996 | 2014 |
| Metric | EFSI | LRMR |
|---|---|---|
| Price | $45.97 | $2.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $47.00 | $14.40 |
| AVG Volume (30 Days) | 38.2K | ★ 1.4M |
| Earning Date | 10-22-2026 | 11-24-2026 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.49 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.52 | N/A |
| P/E Ratio | $18.39 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $31.44 | $1.92 |
| 52 Week High | $48.17 | $6.42 |
| Indicator | EFSI | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 52.77 | 51.48 |
| Support Level | $45.07 | $1.92 |
| Resistance Level | $47.73 | $4.19 |
| Average True Range (ATR) | 1.11 | 0.24 |
| MACD | -0.06 | 0.07 |
| Stochastic Oscillator | 40.09 | 75.38 |
Eagle Financial Services Inc is a locally owned and managed financial institution. It offers retail and commercial banking services, including demand, savings and time deposits and consumer, mortgage, and commercial loans. It also offers telephone banking, internet banking, and mobile banking to its customers. The Company has three reportable operating segments, Community Banking, Marine Lending and Wealth Management. It generates a majority of its revenue from the Community Banking segment.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.